跳转至内容
Merck
CN

SML0002

Sigma-Aldrich

C646

≥98% (HPLC), p300/CBP histone acetyltransferase inhibitor, powder

别名:

4-[4-[[5-（4,5-二甲基-2-硝基苯基）-2-呋喃基] 亚甲基]-4,5-二氢-3-甲基-5-氧代-1H-吡唑-1-基] 苯甲酸

登录查看公司和协议定价

关于此项目

经验公式（希尔记法）:
C24H19N3O6
CAS Number:
328968-36-1
分子量:
445.42
MDL编号:
MFCD01784780
UNSPSC代码:
12352200
PubChem化学物质编号:
329825079
NACRES:
NA.77

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

Product Name

C646, ≥98% (HPLC)

质量水平

100

方案

≥98% (HPLC)

表单

powder

储存条件

desiccated

颜色

red to brown

溶解性

DMSO: >25 mg/mL

储存温度

2-8°C

SMILES字符串

Cc1cc(-c2ccc(\C=C3\C(C)=NN(c4ccc(cc4)C(O)=O)C3=O)o2)c(cc1C)[N+]([O-])=O

InChI

1S/C24H19N3O6/c1-13-10-20(21(27(31)32)11-14(13)2)22-9-8-18(33-22)12-19-15(3)25-26(23(19)28)17-6-4-16(5-7-17)24(29)30/h4-12H,1-3H3,(H,29,30)/b19-12-

InChI key

HEKJYZZSCQBJGB-UNOMPAQXSA-N

相关类别

应用

采用 C646 研究 p300 在慢性压迫性损伤大鼠慢性神经病理性疼痛中的作用。

生化/生理作用

C646 是 p300 和 CBP (p300/CBP) 组蛋白乙酰转移酶的强效、细胞渗透性和选择性抑制剂。C646 抑制 p300/CBP 影响多种转录因子如 NF-κ 的活性p53 和 MyoD 与生理学、疾病过程、海马突触可塑性、空间记忆和情境恐惧相关。
C646 是一种强效、竞争性、选择性组蛋白乙酰转移酶 (HAT) p300/CBP 抑制剂。
C646 是一种竞争性组蛋白乙酰转移酶 (HAT) p300/CBP 抑制剂，Ki 为 400 nM，与其他乙酰转移酶相比具有选择性。

特点和优势

该化合物是基因调控研究的特色产品。 点击此处 ，发现更多特色基因调控产品。在 sigma.com/discover-bsm了解更多关于其他研究领域的生物活性小分子。

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000235500
0000235500
0000144044
0000106340
0000092118

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Jia Cao et al.
Nature communications, 8(1), 131-131 (2017-07-27)
Diabetes and obesity are characterized by insulin resistance and chronic low-grade inflammation. An elevated plasma concentration of lipopolysaccharide (LPS) caused by increased intestinal permeability during diet-induced obesity promotes insulin resistance in mice. Here, we show that LPS induces endoplasmic reticulum
A R Esteves et al.
Biochimica et biophysica acta. Molecular basis of disease, 1865(8), 2008-2023 (2018-12-21)
Protein post-translational modifications (PTMs) that potentiate protein aggregation have been implicated in several neurological disorders, including Alzheimer's (AD) and Parkinson's disease (PD). In fact, Tau and alpha-synuclein (ASYN) undergo several PTMs potentiating their aggregation and neurotoxicity. Recent data posits a
Erin M Bowers et al.
Chemistry & biology, 17(5), 471-482 (2010-06-11)
The histone acetyltransferase (HAT) p300/CBP is a transcriptional coactivator implicated in many gene regulatory pathways and protein acetylation events. Although p300 inhibitors have been reported, a potent, selective, and readily available active-site-directed small molecule inhibitor is not yet known. Here
Liduan Zheng et al.
Scientific reports, 7(1), 8967-8967 (2017-08-23)
Recent evidence shows the emerging roles of promoter-targeting endogenous microRNAs (miRNAs) in regulating gene transcription. However, miRNAs affecting the transcription of matrix metalloproteinase 14 (MMP-14) in gastric cancer remain unknown. Herein, through integrative mining of public datasets, we identified the
Bin Liu et al.
Cancers, 11(4) (2019-04-03)
KRAS-driven non-small cell lung cancer (NSCLC) patients have no effective targeted treatment. In this study, we aimed to investigate targeting epidermal growth factor receptor (EGFR) as a therapeutic approach in KRAS-driven lung cancer cells. We show that ablation of EGFR
查看所有相关文献

商品

Discover Bioactive Small Molecules for Gene Regulation

We offer a variety of small molecule research tools, such as transcription factor modulators, inhibitors of chromatin modifying enzymes, and agonists/antagonists for target identification and validation in gene regulation research; a selection of these research tools is shown below.

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持